NARLA
LAB
07 / 16 / 2021
Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents
10 / 07 / 2020
The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies
12 / 10 / 2019
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
09 / 27 / 2019
Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)
09 / 20 / 2019
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors
05 / 29 / 2019
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis
07 / 17 / 2018
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
04 / 01 / 2018
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer
05 / 15 / 2017
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
10 / 28 / 2015
All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase
12 / 16 / 2014
Repurposing of bisphosphonates for the prevention and therapy of non-small cell lung and breast cancer
01 / 07 / 2014
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition
01 / 23 / 2013
KLF6-SV1 drives breast cancer metastasis and is associated with poor survival
06 / 01 / 2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
07 / 01 / 2005
Targeted inhibition of the KLF6 splice variant KLF6SV1 suppresses prostate cancer growth and spread
02 / 01 / 2005
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk
04 / 01 / 1995